Biopsy-based prediction and prognosis in inflammatory bowel disease Group Lugli Our group works on extracting information from colorectal tissue biopsies to aid prognosis of disease evolution and prediction of therapy success in patients with inflammatory bowel disease (IBD). In Bern, we are working on implementing the IBD-DCA score in clinical practice. In parallel, we are establishing its prognostic value and develop an AI algorithm to automatize the scoring. In collaboration with gastroenterologists in Europe (Switzerland, Netherlands), we hope to identify tissue-based markers that allow a personalized treatment strategy in asymptomatic patients diagnosed with IBD during colorectal cancer screening. Schematic overview of how information extracted from colorectal biopsies may be used to guide treatment strategy in asymptomatic patients diagnosed with inflammatory bowel disease during colon cancer screening.